官方服务：
资源简介：
Novel RORg inverse agonists do not modulate androgen receptor activity in prostate cancer
应用场景：
创建时间：
2025-01-23
相关数据集
Novel RORg inverse agonists do not modulate androgen receptor activity in prostate cancer. Novel RORg inverse agonists do not modulate androgen receptor activity in prostate cancer
Work published by Wang et al. described pharmacological inhibition of RORg with an inverse agonist (SR2211) which led to a decrease in AR gene expression and a reduction in AR protein, which led to th
NIAID Data Ecosystem90
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Aberrant activation of the androgen receptor (AR) plays a key role in the progression of prostate cancer. Current strategies to ablate AR signalling are circumvented when castration resistant prostate
NIAID Data Ecosystem40
Structure–Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD + ‑Dependent Lysine Deacylase Sirtuin 2
The NAD+-dependent lysine deacylase sirtuin 2 (Sirt2) is involved in multiple pathological conditions such as cancer. Targeting Sirt2 has thus received an increased interest for therapeutic purposes.
NIAID Data Ecosystem20
RNA oligonucleotide sequences.
The increasing incidence of prostate cancer (PCa) indicates an urgent need for the development of new effective drug therapy. There are limited options to treat the PCa, this study tried to determine
NIAID Data Ecosystem40
Supplementary Table 2 from Relationships between Circulating and Intraprostatic Sex Steroid Hormone Concentrations
Supplementary Table 2: Reproducibility of average tissue hormone assays by zone and overall from a pilot study of 30 men recruited at George Washington University Medical Center that included a total
NIAID Data Ecosystem30
